Centiva Capital, LP Uni Qure N.V. Transaction History

Centiva Capital, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $79,251 - $139,724	11,811 New	11,811 $79,000
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $3,029 - $3,737	-162 Reduced 5.59%	2,738 $55,000
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $52,548 - $79,228	2,900 New	2,900 $65,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.